Cheah Ming T, Chen James Y, Sahoo Debashis, Contreras-Trujillo Humberto, Volkmer Anne K, Scheeren Ferenc A, Volkmer Jens-Peter, Weissman Irving L
Institute of Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305; Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University, Stanford, CA 94305;
Institute of Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305; Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University, Stanford, CA 94305; Department of Pediatrics, University of California, San Diego, La Jolla, CA 92093;
Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4725-30. doi: 10.1073/pnas.1424795112. Epub 2015 Mar 30.
Nonresolving chronic inflammation at the neoplastic site is consistently associated with promoting tumor progression and poor patient outcomes. However, many aspects behind the mechanisms that establish this tumor-promoting inflammatory microenvironment remain undefined. Using bladder cancer (BC) as a model, we found that CD14-high cancer cells express higher levels of numerous inflammation mediators and form larger tumors compared with CD14-low cells. CD14 antigen is a glycosyl-phosphatidylinositol (GPI)-linked glycoprotein and has been shown to be critically important in the signaling pathways of Toll-like receptor (TLR). CD14 expression in this BC subpopulation of cancer cells is required for increased cytokine production and increased tumor growth. Furthermore, tumors formed by CD14-high cells are more highly vascularized with higher myeloid cell infiltration. Inflammatory factors produced by CD14-high BC cells recruit and polarize monocytes and macrophages to acquire immune-suppressive characteristics. In contrast, CD14-low BC cells have a higher baseline cell division rate than CD14-high cells. Importantly, CD14-high cells produce factors that further increase the proliferation of CD14-low cells. Collectively, we demonstrate that CD14-high BC cells may orchestrate tumor-promoting inflammation and drive tumor cell proliferation to promote tumor growth.
肿瘤部位无法消退的慢性炎症一直与促进肿瘤进展和患者预后不良相关。然而,建立这种促肿瘤炎症微环境的机制背后的许多方面仍不明确。以膀胱癌(BC)为模型,我们发现与CD14低表达的癌细胞相比,CD14高表达的癌细胞表达更高水平的多种炎症介质,并且形成的肿瘤更大。CD14抗原是一种糖基磷脂酰肌醇(GPI)连接的糖蛋白,已被证明在Toll样受体(TLR)的信号通路中至关重要。癌细胞的这个BC亚群中CD14的表达对于增加细胞因子产生和促进肿瘤生长是必需的。此外,由CD14高表达细胞形成的肿瘤血管化程度更高,髓样细胞浸润也更多。CD14高表达的BC细胞产生的炎性因子招募并极化单核细胞和巨噬细胞,使其获得免疫抑制特性。相比之下,CD14低表达的BC细胞的基线细胞分裂率高于CD14高表达的细胞。重要的是,CD14高表达的细胞产生的因子会进一步增加CD14低表达细胞的增殖。总体而言,我们证明CD14高表达的BC细胞可能协调促肿瘤炎症并驱动肿瘤细胞增殖以促进肿瘤生长。